Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
HOHOOKIPA Pharma Inc. logo

HOOKIPA Pharma Inc. (HOOK)

Other OTC · Currency in USD
$1.15 ▲ +0.00 (+0.00%)
At close: Jul 17, 9:30 AM ET. Market closed.

Summary

Previous Close
$1.15
Open
$1.15
Day's Range
$1.15 – $1.15
52 Week Range
$0.81 – $1.55
Volume
0
Avg. Volume
11,964
Market Cap
$14.40M
Beta (5Y Monthly)
0.77
PE Ratio (TTM)
--
EPS (TTM)
-$1.09
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$3.00

Profile: HOOKIPA Pharma Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
82
CEO
Malte Peters

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company’s immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial.

Earnings

DateEst.Actual
Nov 14, 2025-$0.76$0.09Beat
Sep 30, 2025-$0.61-$0.40Beat
May 15, 2025-$0.61-$1.23Miss
Feb 27, 2025-$0.41-$1.96Miss
Nov 14, 2024-$1.28-$1.10Beat
Aug 9, 2024-$1.44-$1.52Miss

Analyst view

Consensus price target
$3.00 ▲ +160.9%
Range $3.00 – $3.00
Rating: Buy
Buy 56% · Hold 33% · Sell 11%

Get free alerts on HOOK and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.